Open source option
Dudes and all you systems biology enthu's , check this out, Novartis, The Broad Institute, and Lund University announced the completion of a genome-wide map of genetic differences in humans and their relationship to type 2 diabetes and other metabolic disorders. All results of the analysis are being made accessible, free of charge on the internet to scientists around the world ( Novartis Media Release, Feb 12, 2007 ) The results of this study are available at http://www.broad.mit.edu/diabetes/ Has the increasing complexity of genome-wide studies and other large-scale systems biology datasets reached a threshold that makes the open source option more attractive to the pharma industry?